Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Sky One Listed On NASDAQ, Recognized By Chinese Government For Innovation With Prestigious Award

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China Sky One Medical has succeeded in having its shares listed on the NASDAQ Global Select Market in a move that Sky's CEO said demonstrates the company's solid financial performance over the past three years and strong future outlook

You may also be interested in...



China Sky One Obtains CE Marks As It Sets Its Sights On International Markets

SHANGHAI - NASDAQ-listed China Sky One Medical has received European Union CE Mark status for its Myocardial Infarction and Urine Microalbumin diagnostic test kits. Meeting the EU health and safety standards of products ensures the company can expand to international markets, and it is now seeking partnerships with leading international distributors

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel